Business
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today results showing significant effects of Aramchol in pre-clinical models of primary sclerosing cholangitis (PSC).
About this update from Galmed Pharmaceuticals Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Aramchol, an SCD1 inhibitor, significantly attenuates and prevents biliary fibrosis in mouse models of primary sclerosing cholangitis (PSC)","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"Aramchol treatment leads to significant inhibition (2-fold, p<0.05) of TGFβ-induced hepatic fibrosis pathways while upregulating peroxisome proliferator activated receptor (PPAR) signaling","length":191,"tagName":"p"}]},{"val":[{"type":"text","content":"Aramchol's effect in the prevention and treatment of biliary and hepatic fibrosis, provides the rationale for assessing Aramchol in further clinical studies in patients with fibrosis driven liver cancers","length":207,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":537,"olType":false},{"type":"text","content":"TEL AVIV, Israel, May 13, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today results showing significant effects of Aramchol in pre-clinical models of primary sclerosing cholangitis (PSC).","length":369,"tagName":"p"},{"type":"image","alt":"Galmed_Pharmaceuticals_Logo","displaySize":"","headline":null,"caption":"Galmed_Pharmaceuticals_Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":95,"url":"https://media.zenfs.com/en/prnewswire.com/0bd7ffdcf08721d90a3bcb5658c1e61e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rkpv_HpbOjVKPN_v6KG17Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0bd7ffdcf08721d90a3bcb5658c1e61e","width":400,"height":95}}},{"type":"text","content":"Fibroinflammatory cholangiopathies, such as PSC and primary biliary cholangitis (PBC), are characterized by cholestatic injury, inflammation and fibrosis-induced obstruction of ducts, driving disease-related complications.","length":222,"tagName":"p"},{"type":"text","content":"Aramchol, an SCD-1 inhibitor, both attenuated and prevented biliary fibrosis in mouse models of PSC. Aramchol significantly reduced, in a dose-dependent manner, the increased expression of the fibrotic marker plasminogen activator inhibitor-1 and hepatic stellate cell-activating genes (VEGFA and PDGFB) in TGFβ-activa...